Calidi Biotherapeutics, Inc.
CLDWW- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001855485
No open-market purchases or sales by Calidi Biotherapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesCLDI
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CLDWW, Q2 2026
No superinvestor reported holding CLDWW at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Calidi Biotherapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 16, 2025 (view filing) | Dec 12 | 4 days | Camaisa AllanDirector | SSale | −850 | $1.46 | −$1.24K | −1.1%77.0K after | |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Schoeneck James ADirector | PPurchase | +75.0K | $2.00 | +$150.0K | +6,613.8%76.1K after | |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Schoeneck James ADirector | PPurchase | +75.0K | – | – | –75.0K after | Derivative |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Poma Eric EChief Executive Officer | PPurchase | +25.0K | $2.00 | +$50.0K | New position25.0K after | |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Poma Eric EChief Executive Officer | PPurchase | +25.0K | – | – | –25.0K after | Derivative |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Leftwich ScottDirector | PPurchase | +125.0K | $2.00 | +$250.0K | +2,212.4%130.7K after | |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Leftwich ScottDirector | PPurchase | +125.0K | – | – | –125.0K after | Derivative |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Jackson Andrew C.Chief Financial Officer | PPurchase | +2.50K | $2.00 | +$5.00K | New position2.50K after | |
| Aug 25, 2025 (view filing) | Aug 21 | 4 days | Jackson Andrew C.Chief Financial Officer | PPurchase | +2.50K | – | – | –2.50K after | Derivative |
| Dec 18, 2024 (view filing) | Dec 17 | 1 day | Camaisa AllanCEO and Chairman of the Board | SSale | −10.0K | $1.62 | −$16.2K | −13.0%66.7K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Calidi Biotherapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding CLDWW in 13F filings for Q2 2026.